Supriya Peshin, Internal Medicine Resident Physician at Ballad Health, shared on X:
“Excited to share our review on KRAS-targeted therapies in pancreatic cancer.
Daraxonrasib (RMC-6236) is especially promising, demonstrating a significant survival benefit over chemotherapy in previously treated patients with metastatic PDAC.
A meaningful step toward making precision oncology a reality in pancreatic cancer.”
Title: Advances in KRAS-Targeted Therapies for Pancreatic Cancer
Authors: Supriya Peshin, Afra Zahid, Ehab Takrori, Zahra Hamedi, Shafia Rahman
You can also read:
